Listen: Pharma’s lobbying dollars, Alnylam’s future, and diversity in Covid-19 studies

Is pharma scared of Kamala Harris? Are there second acts in biotech? And why aren’t Covid-19 clinical trials enrolling diverse participants?

We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Lev Facher joins us to talk about Sen. Kamala Harris’ health care record and how the drug industry is spending its lobbying dollars in 2020. Then, soon-to-be-former Alynlam Pharmaceuticals President Barry Greene calls in to look back on his career at the ascendant company and at what comes next. Finally, oncologist Hala Borno joins us to discuss the lack of diversity in Covid-19 trials and why science has to do better.

For more on what we cover, here’s the latest on drug industry lobbying; here’s Borno’s Covid-19 research; and here’s STAT’s complete coverage of the coronavirus pandemic.

We’ll be back next Thursday evening — and every Thursday evening — so be sure to sign up on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].